ECHO-310: A phase 3, randomized trial of epacadostat plus nivolumab plus chemo vs EXTREME as first-line treatment of recurrent/metastatic SCCHN.

被引：1
|
作者：
Cohen, Ezra E. W.
Mehra, Ranee
Psyrri, Amanda
Bauman, Julie E.
Schaub, Richard
Zhou, Li
Li, Li
Jayaprakash, Vijayvel
Guigay, Joel
机构：
[1] Univ Calif San Diego, La Jolla, CA 92093 USA
[2] Johns Hopkins Med Ctr, Baltimore, MD USA
[3] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Athens, Greece
[4] Univ Arizona, Coll Med, Tucson, AZ USA
[5] Incyte Corp, Wilmington, DE USA
[6] Bristol Myers Squibb, Princeton, NJ USA
[7] Ctr Antoine Lacassagne, Nice, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS6092
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS6092
引用
收藏
页数：2
相关论文
共 50 条
  • [41] PHASE II TRIAL OF FIRST-LINE CAPECITABINE PLUS OXALIPLATIN IN PATIENTS WITH METASTATIC NASOPHARYNGEAL CARCINOMA
    Chua, D.
    Ng, W. T.
    Ng, W. Y.
    Lui, C. Y.
    Li, V.
    Cheng, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 324 - 324
  • [42] Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer
    Ilhan, Yusuf
    Tatli, Ali Murat
    Teker, Fatih
    Onder, Arif Hakan
    Kose, Fatih
    Geredeli, Caglayan
    Karaagac, Mustafa
    Kaplan, Muhammet Ali
    Inanc, Mevlude
    Aydin, Sabin Goktas
    Kargi, Aysegul
    Arak, Haci
    Ozturk, Banu
    Besen, Ali Ayberk
    Selvi, Oguzhan
    Korkmaz, Mustafa
    Oruc, Zeynep
    Bozkurt, Oktay
    Bilici, Ahmet
    Bayram, Selami
    Dae, Shute Ailia
    Ozdogan, Mustafa
    Coskun, Hasan Senol
    Goksu, Sema Sezgin
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 (04) : 502 - 507
  • [43] Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study)
    Nakayama, Goro
    Mitsuma, Ayako
    Sunagawa, Yuki
    Ishigure, Kiyoshi
    Yokoyama, Hiroyuki
    Matsui, Takanori
    Nakayama, Hiroshi
    Nakata, Kazuhiko
    Ishiyama, Akiharu
    Asada, Takahiro
    Umeda, Shinichi
    Ezaka, Kazuhiro
    Hattori, Norifumi
    Takami, Hideki
    Kobayashi, Daisuke
    Tanaka, Chie
    Kanda, Mitsuro
    Yamada, Suguru
    Koike, Masahiko
    Fujiwara, Michitaka
    Fujii, Tsutomu
    Murotani, Kenta
    Ando, Yuichi
    Kodera, Yasuhiro
    ONCOLOGIST, 2018, 23 (08): : 919 - 927
  • [44] Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib plus paclitaxel vs trastuzumab plus paclitaxel as first-line treatment for HER2+metastatic breast cancer (NEfERTT)
    Awada, Ahmad
    Colomer, Ramon
    Bondarenko, Igor
    Inoue, Kenichi
    Badwe, Rajendra A.
    Demetriou, Georgia
    Wang, Xiaojia
    Smirnov, Vitaly
    Lee, Soo-Chin
    Mehta, Ajay O.
    Kim, Sung-Bae
    Shen, Zhen-Zhou
    Bachelot, Thomas Denis
    Goswami, Chanchal
    Deo, S. V. S.
    Bose, Ron
    Wong, Alvin
    Xu, Feng
    Bryce, Richard
    Carey, Lisa A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] Randomized phase II trial of CapOX plus bevacizumab versus CapIRI plus bevacizumab as first-line treatment in Japanese patients with metastatic colorectal cancer (CCOG-1201).
    Sasahara, Masahiro
    Nakayama, Goro
    Ishigure, Kiyoshi
    Yokoyama, Hiroyuki
    Uehara, Keisuke
    Ishiyama, Akiharu
    Matsui, Takanori
    Nakayama, Hiroshi
    Kobayashi, Daisuke
    Umeda, Shinichi
    Sunagawa, Yuki
    Murotani, Kenta
    Ando, Yuichi
    Kodera, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [46] Randomized Phase III Trial of Gemcitabine Plus Docetaxel Plus Bevacizumab or Placebo As First-Line Treatment for Metastatic Uterine Leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study
    Hensley, Martee L.
    Miller, Austin
    O'Malley, David M.
    Mannel, Robert S.
    Behbakht, Kian
    Bakkum-Gamez, Jamie N.
    Michael, Helen
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (10) : 1180 - 1185
  • [47] FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial
    Damato, Angela
    Bergamo, Francesca
    Antonuzzo, Lorenzo
    Nasti, Guglielmo
    Iachetta, Francesco
    Romagnani, Alessandra
    Gervasi, Erika
    Larocca, Mario
    Pinto, Carmine
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [48] POSEIDON: A phase 3 study of first-line Durvalumab ± Tremelimumab plus chemotherapy vs chemotherapy alone in metastatic NSCLC
    Thomas, M.
    Grohe, C.
    Eberhardt, W.
    Rawluk, J.
    Reck, M.
    Laack, E.
    Wesseler, C.
    Rittmeyer, A.
    Alt, J.
    Reinmuth, N.
    Griesinger, F.
    Kern, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 295 - 295
  • [49] POSEIDON: A Phase 3 Study of First-Line Durvalumab ± Tremelimumab plus Chemotherapy vs Chemotherapy Alone in Metastatic NSCLC
    Mok, T.
    Johnson, M.
    Garon, E.
    Peters, S.
    Soria, J.
    Wang, L.
    Jarkowski, A.
    Dennis, P.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1974 - S1974
  • [50] ECHO-305/KEYNOTE-654: A phase 3, randomized, double-blind study of first-line epacadostat plus pembrolizumab vs pembrolizumab plus placebo for metastatic non-small cell lung cancer (mNSCLC) with high PD-L1 levels
    Awad, Mark M.
    Munteanu, Mihaela
    Zhao, Yufan
    Xu, Lu
    Samkari, Ayman
    Paz-Ares, Luis G.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345